McCollum Christoferson Group LLC Has $999,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

McCollum Christoferson Group LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,909 shares of the company’s stock after selling 200 shares during the period. McCollum Christoferson Group LLC’s holdings in Johnson & Johnson were worth $999,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. IFS Advisors LLC grew its stake in shares of Johnson & Johnson by 138.9% during the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after purchasing an additional 100 shares during the last quarter. Bay Harbor Wealth Management LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at $32,000. RPg Family Wealth Advisory LLC bought a new stake in shares of Johnson & Johnson during the third quarter worth $35,000. Runnymede Capital Advisors Inc. acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at $38,000. Finally, NewSquare Capital LLC boosted its holdings in Johnson & Johnson by 145.8% in the fourth quarter. NewSquare Capital LLC now owns 290 shares of the company’s stock valued at $42,000 after acquiring an additional 172 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In related news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on JNJ. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 19th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Leerink Partners cut their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Wells Fargo & Company decreased their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Finally, Raymond James reduced their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $171.33.

Johnson & Johnson Stock Up 0.2 %

Shares of JNJ stock opened at $163.40 on Monday. The company has a market capitalization of $393.76 billion, a price-to-earnings ratio of 24.57, a P/E/G ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The firm has a fifty day moving average of $156.99 and a 200-day moving average of $156.17. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the business posted $2.29 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.04%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.